Sign In
Buy ALPMY
$13.16
-0.310 (-2.30%)
At Close: Jun 23, 2026
Astellas Pharma, Inc. (ALPMF) CEO Kenji Yasukawa on Q4 2021 Results - Earnings Call Transcript
05:48pm, Tuesday, 27'th Apr 2021
Astellas Pharma, Inc. (ALPMF) CEO Kenji Yasukawa on Q4 2021 Results - Earnings Call Transcript
Astellas Takes $540M Impairment Charge Of $3B Audentes Buyout On Gene Therapy Trial Hold
03:37pm, Tuesday, 27'th Apr 2021
In a financial notice posted earlier today, Astellas Pharma Inc (OTCMKTS: ALPMY) said it was taking an impairment loss of ¥58.8 billion ($540 million) because of last year's FDA clinical hold on Au
Astellas Pharma's Fezolinetant Topped Placebo For Reducing Severity Of Menopausal Hot Flash In Phase 3 Studies
01:08pm, Friday, 19'th Feb 2021
Astellas Pharma Plc (OTCMKTS: ALPMY) has reported positive topline results from two Phase 3 trials, SKYLIGHT 1 and SKYLIGHT 2, evaluating an oral non-hormonal compound, fezolinetant, for treating m
